The stock has a 36-month beta value of 1.67. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 1 as “overweight,” 15 as “hold,” and 2 as “sell.”
The public float for MRNA is 342.76M, and at present, short sellers hold a 9.70% of that float. On November 05, 2024, the average trading volume of MRNA was 4.94M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MRNA) stock’s latest price update
Moderna Inc (NASDAQ: MRNA) has experienced a decline in its stock price by -2.00 compared to its previous closing price of 54.63. However, the company has seen a fall of -2.30% in its stock price over the last five trading days. zacks.com reported 2024-10-31 that Moderna (MRNA) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MRNA’s Market Performance
MRNA’s stock has fallen by -2.30% in the past week, with a monthly drop of -11.06% and a quarterly drop of -34.95%. The volatility ratio for the week is 3.60% while the volatility levels for the last 30 days are 3.56% for Moderna Inc The simple moving average for the past 20 days is -3.32% for MRNA’s stock, with a -46.52% simple moving average for the past 200 days.
Analysts’ Opinion of MRNA
Many brokerage firms have already submitted their reports for MRNA stocks, with Bernstein repeating the rating for MRNA by listing it as a “Mkt Perform.” The predicted price for MRNA in the upcoming period, according to Bernstein is $55 based on the research report published on October 17, 2024 of the current year 2024.
JP Morgan gave a rating of “Underweight” to MRNA, setting the target price at $70 in the report published on September 13th of the current year.
MRNA Trading at -16.52% from the 50-Day Moving Average
After a stumble in the market that brought MRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.59% of loss for the given period.
Volatility was left at 3.56%, however, over the last 30 days, the volatility rate increased by 3.60%, as shares sank -8.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.06% lower at present.
During the last 5 trading sessions, MRNA fell by -2.30%, which changed the moving average for the period of 200-days by -46.30% in comparison to the 20-day moving average, which settled at $55.38. In addition, Moderna Inc saw -46.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNA starting from Mock James M, who sale 715 shares at the price of $60.12 back on Oct 07 ’24. After this action, Mock James M now owns 9,505 shares of Moderna Inc, valued at $42,986 using the latest closing price.
Klinger Shannon Thyme, the Chief Legal Officer of Moderna Inc, sale 551 shares at $73.57 during a trade that took place back on Sep 09 ’24, which means that Klinger Shannon Thyme is holding 18,154 shares at $40,539 based on the most recent closing price.
Stock Fundamentals for MRNA
Current profitability levels for the company are sitting at:
- -0.92 for the present operating margin
- 0.32 for the gross margin
The net margin for Moderna Inc stands at -1.16. The total capital return value is set at -0.35. Equity return is now at value -40.94, with -31.24 for asset returns.
Based on Moderna Inc (MRNA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -5.25. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -165.54.
Currently, EBITDA for the company is -3.62 billion with net debt to EBITDA at 0.6. When we switch over and look at the enterprise to sales, we see a ratio of 3.58. The receivables turnover for the company is 30.99for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.09.
Conclusion
To sum up, Moderna Inc (MRNA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
